Susquehanna International Group, LLP Dbv Technologies S.A. Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.7 - $1.33 $7,469 - $14,192	10,671 New	10,671 $10,000
Q1 2021 May 17, 2021	SELL	$2.75 - $6.57 $174,589 - $417,109	-63,487 Reduced 77.23%	18,715 $100,000
Q4 2020 Feb 16, 2021	BUY	$1.38 - $3.01 $113,438 - $247,428	82,202 New	82,202 $215,000
Q3 2020 Nov 16, 2020	SELL	$1.58 - $4.77 $30,525 - $92,156	-19,320 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$3.74 - $6.28 $154,132 - $258,811	-41,212 Reduced 68.08%	19,320 $85,000
Q4 2019 Feb 14, 2020	SELL	$6.75 - $11.15 $166,414 - $274,892	-24,654 Reduced 28.94%	60,532 $648,000
Q4 2018 Feb 14, 2019	BUY	$5.75 - $21.85 $347,530 - $1.32 Million	60,440 Added 244.24%	85,186 $547,000
Q3 2018 Nov 14, 2018	BUY	$16.81 - $24.58 $226,598 - $331,338	13,480 Added 119.65%	24,746 $556,000
Q2 2018 Aug 14, 2018	SELL	$18.6 - $24.94 $124,266 - $166,624	-6,681 Reduced 37.23%	11,266 $217,000
Q1 2018 May 15, 2018	BUY	$20.86 - $26.6 $374,374 - $477,390	17,947 New	17,947 $414,000

253K

Ticker DBVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,776,992
Market Cap $131M
Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.